Hänninen’s training is also diverse. He did his master’s thesis on medical technology, his MBA work focused on ethical management at Nokia, and his thesis focused on investor reactions to corporate merger and acquisition announcements.
Hänninen is interested in the high technology of Injeq and the global market. It is also important to him that Injeq is a Finnish company whose product can improve people’s lives. “Injeq is a truly international company that creates something new. I see the purpose of the job as an important motivating factor,” says Hänninen.
Hänninen describes himself as a pragmatic leader who leads on the basis of facts. “I am open, listen and respect everyone in the organization. I want to challenge the organization, and as a team player, I believe in innovation by individuals and working together” , believes Hänninen.
“I am very pleased that a professional management CEO with extensive experience and strong business vision has been appointed to Injeq. We are an international growth medical high-tech company that has need expertise like Hänninen”, said the chairman of the board of directors of Injeq and acting. CEO
Hänninen has solid experience in introducing new technologies to the markets. At Nokia, he was selling cellular networks in areas where even wired phone networks didn’t work perfectly.
Phone. +358 40 750 8158
Phone. +358 50 518 1830
Injeq in a nutshell
The IQ-Tip® smart needle is a modern way to safely perform demanding injections for patients. The first step is the lumbar puncture, a clinical procedure in which cerebrospinal fluid is removed or medication is administered into the spinal cavity. The clinical performance and safety of the product in lumbar punctures has been evaluated in three clinical trials at Finnish university hospitals. The smart needle is suitable for lumbar puncture from newborns to the elderly, with one of the main uses being the treatment of children with leukemia.
Founded in 2010, Injeq operates in
(c) Decision 2022. All rights reserved., sources